12:00 AM
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ibrutinib: Additional Phase Ib/II data

Data from 31 evaluable treatment-naïve patients aged 65 and older in the open-label, U.S. Phase Ib/II PCYC-1102-CA trial showed that once-daily 420 mg oral PCI-32765 led to an ORR of 81% at a median follow-up of 14.4 months (n=26), with 3 complete responses and 18 partial responses, plus 1 case of stable disease. Once-daily 840 mg PCI-32765 led...

Read the full 267 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >